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I. INTRODUCTION 
 
 “Theranostics” is a new medical concept that combines diagnosis and therapy. In vivo 
visualization using MRI contrast agents and/or fluorescent probes is useful to assess 
diseases and therapeutic efficacy. In addition, probes that combine contrast agents and 
therapeutic molecules can allow “image-guided” precision medicine before, during and 
after therapy. In our study, we developed LP-iDOPE, which incorporates indocyanine 
green (ICG) in liposome membranes, and applied it to glioblastoma model rats. 
 
GM 
 Glioblastoma multiforme (GM) is the most common primary malignant brain tumor. It 
is known to be highly invasive and intractable. The median survival time of GM 
patients is only 1-2 years with standard surgery and radiation treatments (DeAngelis, 
2001 January 11; Krex et al., 2007). After taking Temozolomide, an oral alkylating 
agent, the median survival time of GM patients was reported to be 14.6 months in recent 
clinical trials (Stupp et al., 2005 Mar 10). Another study has reported that 73.5% of 
patients died within 2 years and the recurrence rate after surgery was 72.2% (Brandes et 
al., 2009 Mar 10). The high invasiveness and high recurrence rate of GM is a big 
problem. Extended resection is often performed to completely eliminate tumor cells, but 
this inevitably scratches the surrounding normal brain tissue (Hasegawa et al., 2010).  
 
 
ICG 
 Indocyanine green (ICG), which is a small water-soluble dye know since the 1950's, 
has an absorption and fluorescence spectrum in the near infrared (NIR) region (600 to 
1200 nm). ICG is widely used in biomedical research and clinical applications as a 
biomarker or a contrast agent in studies involving the heart, liver, lungs and blood 
circulation due to its biocompatibility (Flower & Hochheimer, 1976 Feb). The use of 
NIR fluorescence imaging in vivo offers the advantage that tissue autofluorescence is 
very low so that interference is minimized, optimum contrast is easily obtained and 
deeper penetration of the signal is possible. However, the half-life of ICG in blood is as 
short as 3-4 minutes, so practical imaging time is around 15 minutes.(Belykh et al., 
2016; Cherrick, Stein, Leevy, & Davidson, 1960 Apr)  
 
PTT/PDT 
 There has been an on-going effort to utilize ICG in conjunction with biomolecules to 
afford diagnosis, and photothermal therapy (PTT) and photodynamic therapy (PDT) of 
cancer.(Olzowy et al., 2002 Oct; Quirk et al., 2015) 
PTT refers to efforts to use electromagnetic radiation, such as infrared wavelengths, for 
the treatment of various diseases, including cancer. When the temperature rises between 
45°C to 300°C, therapeutic effects can be obtained at sufficient depths using NIR 
irradiation. 
 PDT provides additional specificity to therapeutic techniques becanse irradiated light  
is applied only to the diseased tissue and there is little damage to the surrounding 
benign tissue. This spatial specificity and minimal-invasiveness make PTT an attractive 
therapeutic modality is comparison to open surgery or other invasive therapeutic 
procedures. PDT is believed to act through cytotoxic singlet oxygen (reactive oxygen 
species). Singlet oxygen is formed when a photosensitizer is excited by light and 
transfers its energy to the molecular oxygen in tissues. The oxidization of the singlet 
oxygen may be the principal way tumor cells are destroyed in PDT. 
 
PEGylated Liposome 
 Liposomes have promised to be drug carriers for clinical application since the 1970s 
(Hill & Bangham, 1975). However, simple liposomes have poor blood retention in vivo 
as they are captured in by the reticuloendothelial system (RES). Allen et al. (Allen, 
Hansen, Martin, Redemann, & Yau-Young, 1991 Jul 1) proposed a modified liposome 
with polyethylene glycol on the surface (PEGylated Liposome). The PEG on the 
liposome inhibits albumin adsorption by making the hydration layer thay makes is 
difficult for to phagocytes recognize. PEGylated liposome has long blood retention and 
this opens the way for clinical application. Additionally, in the 1980s, Maeda et al. 
(Maeda, 2015 Aug 30) discovered the enhanced permeability and retention (EPR) effect , 
where particles of approximately 100-300 nm diameter can accumulate in tumor or 
inflamed tissues. PEGylated liposomes have a diameter of around 100-300 nm and are 
therefore expected to accumulate in the tumor while circulating for a long time in the 
blood stream. 
 
PTT/PDT using ICG conjugated PEGylated Liposome 
 Our goal is to establish a theranostic application for (1) accumulating PEGylated 
liposomes carrying ICG to tumors, (2) fluorescent enhancement of the tumor tissue for 
NIR imaging, and (3) treatment of the tumor with PDT.  
 Accumulation of PEGylated Liposome in the tumor clarifies the boundary between 
normal tissue and tumor tissue so that strong imaging contrast can be maintained for 
longer observation time. In the case of resectional surgery for brain tumor, our system 
can reduce the damage for normal brain tissue and help more accurate resection. In 
addition, PDT may prevent tumor recurrence from the boundary of the resection. All of 
these benefits benefiits lead to minimizing side effects. The ICG conjugated PEGylated 
Liposome may also increase the effectiveness of brain tumor resection surgery, thus 
improving the survival rate and quality of life of GM patients. 
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II. Liposomally formulated phospholipid-conjugated indocyanine green for 
intra-operative brain tumor detection and resection 
 
Abstract 
 Some tumor-specific near-infrared (NIR) fluorescent dyes such as indocyanine green 
(ICG), IDRye800CW, and 5-aminolevulinic acid have been used clinically for detecting 
tumor margins or micro-cancer lesions. In this study, we evaluated the physicochemical 
properties of liposomally formulated phospholipid-conjugated ICG, denoted by 
LP-iDOPE, as a clinically translatable NIR imaging nanoparticle for brain tumors. We 
also confirmed its brain-tumor-specific biodistribution and its characteristics as the 
intra-operative NIR imaging nanoparticles for brain tumor surgery. These properties of 
LP-iDOPE may enable neurosurgeons to achieve more accurate identification and more 
complete resection of brain tumor. 
 
1. Introduction 
 Gliomas are the most common type of primary brain tumor and are classified into four 
categories according to the World Health Organization (WHO) grading system: 
low-grade (WHO Grade I and II) and high-grade (WHO Grade III and IV). (Kleihues et 
al.,1993) The complete removal of brain tumor tissues by extended resection is usually 
hard to perform without injuring surrounding normal brain tissues. (Schucht et al., 
2015) It is therefore a challenge for neurosurgeons to remove brain tumor tissues 
completely by resection; leaving any cancer tissues behind can lower the patient's 
quality of life (QOL) and reduce survival times. (Talibi et al., 2014; Tate, 2015) Awide 
range of clinical applications have been developed in attempts to achieve more 
complete brain tumor resections (Keunen et al., 2014). However, accurate identification 
of the tumor region that needs to be resected is still of great importance in brain tumor 
surgery (Kircher et al., 2012; Jermyn et al., 2015). Over the past decade, intra-operative 
imaging using near-infrared (NIR) fluores- cence techniques has entered the surgical 
theatre to fill the gap between pre-operative imaging and intra-operative reality (Vahr- 
meijer et al., 2013; de Boer et al., 2015). Some tumor-specific NIR fluorescent dyes 
have been approved for clinical tumor imaging: indocyanine green (ICG) has been used 
as a targeted free NIR dye for micro-cancer imaging and breast cancer assisted sentinel 
lymph node mapping; IRDye800CW, conjugated with antibody targeting 
VEGF-bevacizumab (VEGF: vascular endothelial growth factor) has completed 
preclinical toxicity studies, and is currently undergoing clinical trials as a NIR dye 
conjugate for early cancer detection; 5-aminolevulinic acid, preferentially taken up by 
tumor cells leading to biosynthesis and accumulation of protoporphyrin IX, has been 
approved in Germany and Japan as an activatable NIR dye for imaging malignant 
gliomas (Luo et al., 2011; Keereweer et al., 2013; Swanson et al., 2015). 
 Intravenous injection of ICG was approved by the Food and Drug Administration in 
the 1950s for several clinical applications and has been shown to have a low 
negative-reaction profile (Dzurinko et al., 2004). The first application of ICG for 
macroscopic demarcation of brain tumor margins was investigated in 1993 (Hansen et 
al., 1993). However, this technique is not effective in distinguishing between tumor 
regions and normal regions of the brain that may incidentally uptake the injected dye 
(Tamura et al., 2012). Cellular visualization using ICG as a contrast agent is therefore 
needed to overcome these limitations. The investigation of potential imaging techniques 
in the field of brain tumor surgery, and the development of new imaging dyes and 
accommodated devices that are available during brain tumor surgery are therefore 
important (Zehri et al., 2014). In this study, we attempted to improve the specificity and 
sensitivity of brain tumor imaging using an ICG fluorophore (Murahari and Yergeri, 
2013). We previously developed a novel NIR fluorescent probe in which an ICG 
fluorophore is covalently conjugated with 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), denoted by iDOPE, for 
incorporation into liposome bilayers as liposomally formulated iDOPE (LP-iDOPE) 
(Suganami et al., 2012). We then evaluated the characteristics of LP-iDOPE as a 
clinically translatable fluorescent nanoparticle for brain tumors, based on the enhanced 
permeability and retention (EPR) effect, and as a NIR fluorescent dye for 
intra-operative identification of brain tumors. We presume that LP-iDOPE is potentially 
of great value as a NIR fluorescence image-guidance intra-operative dye, which could 
make a clear demarcation at brain tumor borders. 
 
2. Material and methods 
 iDOPE was prepared as previously reported (Suganami et al., 2012). Cholesterol 
(1.0x10-3 M, Nippon Fine Chemical Co., Ltd., Tokyo, Japan), 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC, 7.5x10-3 M, NOF Corporation, 
Tokyo, Japan), N-(carbonyl- methoxypolyethyleneglycol 
5000)-1,2-distearoly-sn-glycero-3- phosphoethanolamine sodium salt (DSPE-PEG, 0.5 
mM, NOF Corporation), and iDOPE (2.5 x 10-3M, iDOPE/DOPC molar ratio of 1/3) 
were dissolved in a mixed organic solvent consisting of CH3OH/CHCl3 (volume ratio: 
1/9). A thin lipid film was formed by removal of the solvent under reduced pressure. 
After addition of an aqueous buffered solution (phosphate buffered saline [PBS], pH 
7.4) at room temperature, the liposome dispersion was filtered through a 0.1-mm pore 
polycarbonate filter attached to a LiposoFast-Stabilizer (Avestin Inc., Ottawa, Canada).  
 
2.2. Molecular modeling 
 The three-dimensional structure of ICG was constructed using MOE (version 2009, 
CCG Inc., Montreal, Canada) according to PubChem Compound CID 11967809 
(National Center for Biotechnology Information, Bethesda MD, USA). The 
three-dimensional structure of DOPE was constructed using VMD (http://www.ks.unic. 
edu/). The three-dimensional structures of ICG and DOPE were used to construct that of 
iDOPE using the build command in MOE. Molecular mechanics calculations were 
performed to obtain the local minimum structures of partial membrane region of 
LP-iDOPE, containing DOPC and iDOPE, using the AMBER99 force field in MOE.  
 
2.3. Measurement of particle size 
 Particle size analysis of LP-iDOPE was performed using dynamic light-scattering 
measurements (SZ-100, HORIBA Ltd., Kyoto, Japan). 
 
2.4. UV–vis–NIR and fluorescence spectroscopy 
 The absorption spectra of LP-iDOPE and ICG dissolved in an aqueous buffered 
solution [phosphate buffered saline (PBS), pH 7.4] at room temperature were obtained 
using a UV–vis–NIR spectrometer (UV-3500, Shimadzu, Kyoto, Japan). Fluorescence 
emissions from LP-iDOPE and ICG dissolved in an aqueous buffered solution (PBS, pH 
7.4) at room temperature were observed using a fluorescence spectrometer (F-4500, 
Hitachi, Tokyo, Japan).  
 
2.5. Animals 
 All animal procedures were approved by the Institutional Animal Care and Use 
Committee of Chiba University and the National Institute of Radiological Sciences. 
Male 7- to 8-week-old Fisher 344 rats were obtained from the Japan SLC, Inc. 
(Hama-matsu, Japan). Orthotopic glioma model of 9L-L/R cells in rats: A density of 
5x105 9L-L/R cells with 10µL PBS were injected into rat brains using a microinjector 
(Harvard Apparatus, South Natick, MA, USA). Briefly, the rats were anesthetized with 
2.0% isoflurane (Abbott Japan, Tokyo, Japan) and placed in a stereotactic apparatus. A 
burr hole was made at an appropriate location (1 mm posterior to the bregma and 3 mm 
right of the midline). A 25-gauge needle was inserted at a point 3 mm ventral from the 
dura. These experiments were also done in accordance with the recommendations for 
the proper care and use of laboratory animals and according to The Law No. 105 and 
Notification No. 6 of the Japanese Government.  
 
2.6. MRI 
 All rats were anesthetized with 2.0% isoflurane (Abbott Japan, Tokyo, Japan) and 
administrated with 0.4 ml of Gd-DTPA (Meglu-mine Gadopentetate, 0.002 ml/g, 50 
mmol/l, Bayer, Leverkusen, Germany) intraperitoneally 15 min before MRI 
measurements. All MRI experiments were performed using a 7.0T horizontal MRI 
scanner (Magnet: Kobelco and JASTEC, Kobe, Japan; Console: Bruker Biospin, 
Ettlingen, Germany), with a volume coil for transmission (Bruker Biospin) and an 
eight-channel phased array surface coil for reception (Rapid Biomedical, Rimpar, 
Germany). Multi-slice T1-weighted MR images covering the entire brain (T1WI; 
multi-slice spin echo, TR/TE = 400/9.57 ms, slice thickness = 1.0 mm, slice gap = 0, 
number of slices = 16, matrix = 256 x 256, field of view = 25.6 x 25.6 mm2, average = 
4) were acquired. The slice orientation was trans, axial for all scans. Image 
reconstruction and analysis were performed using ParaVision (Bruker Biospin).  
 
2.7. NIR fluorescence imaging 
 The biodistribution of LP-iDOPE was studied by intravenously injecting LP-iDOPE, 
containing 14.0 mg/kg of LP-iDOPE, through a tail vein of Fisher 344 rats bearing 
9L-L/R cells and imaged at 1 day and 7 days after injection, using an In-Vivo MS FX 
PRO imaging system (Carestream Health, New York, NY, USA).  
 
3. Results and discussion  
3.1. Preparation of LP-iDOPE 
 As part of our on-going research for the development of multi-purpose NIR 
fluorescent liposomes for optical imaging and nanoparticle drug carriers, we rationally 
designed a novel NIR fluorescence probe in which an ICG fluorophore is covalently 
conjugated with DOPE, i.e., iDOPE, for incorporation into liposome bilayers 
(Suganami et al., 2012). As shown in Fig. 1a, we speculate that iDOPE infiltrates the 
lipid membrane by incorporating into 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC). In this study, we selected 10 mol% iDOPE (iDOPE/DOPC molar ratio of 1/10) 
to achieve a high fluorescence intensity by preventing the fluores-cence quenching 
between neighboring iDOPE species (Namiki et al., 2011). The average LP-iDOPE 
diameter should usually be controlled to 100–300 nm in consideration of the EPR effect 
(Maeda, 2015). To confirm that the standard of the EPR effect was met, we filtered the 
liposome dispersion [iDOPE, DOPC, Cholester- ol, and poly ethylene glycol (PEG)] 
through a 100 nm pore polycarbonate filter (Hua et al., 2012). Dynamic light-scattering 
measurements showed that the average LP-iDOPE size was 191 nm (n = 3) (Fig.1b), 
which satisfies the restriction of the EPR effect. This exceeded size, around 90 nm, is 
due to the modification of liposome bilayers with iDOPE and PEG, for a “stealth effect”, 
as shown in Fig. 1a (Ulrich, 2002).  
 
3.2. Physicochemical properties of LP-iDOPE 
 In the past decade, many clinical studies have shown that NIR fluorescence imaging 
during brain tumor surgery is feasible (Zehri et al., 2014; Schaafsma et al., 2011). First, 
to evaluate the properties of LP-iDOPE as a NIR fluorescent liposome, we recorded its 
NIR fluorescence excitation and emission spectra. As shown in Fig. 2, the lmax 
excitation (>780 nm) and lmax emission (811 nm) values of LP-iDOPE shifted to 
longer wave- length than those of ICG (lmax excitation: >780 nm, lmax emission: 800 
nm). We presumed that these phenomena were caused by the liposomal formulation of 
iDOPE, which restricts free movement of the ICG fluorophore and induces a red shift 
(11 nm) of the lmax emission of LP-iDOPE compared with that of ICG (Schaafsma et 
al., 2011). The fluorescence intensity of LP- iDOPE (lmax emission: 811 nm) was about 
15% higher than that of ICG (lmax emission: 800 nm). In this case, we speculated that 
restriction of the ICG fluorophore movement by the liposomally formulation converted 
kinetic energies to fluorescence intensities (Proulx et al., 2010). Based on these results, 
we assumed that the optical properties of LP-iDOPE as a NIR fluorescence-imaging dye 
are nearly the same as those of ICG (Figs. S1 and S2 in Supporting information). We 
therefore concluded that intra-operative NIR- accommodated devices such as pde-neo 
(HAMAMATSU, Japan), HyperEye Medical System (MIZUHO, Japan), and SPY Intra- 
operative Imaging System (NOVADAQ, USA), which are based on intra-operative 
fluorescence imaging techniques using ICG, could be applied in brain tumor surgery, 
using LP-iDOPE, without any regulation changes.  
 
3.3. Tumor-specific localization of LP-iDOPE: magnetic resonance imaging (MRI) 
and NIR 
 As described above, NIR fluorescence image-guided intra-operative techniques using 
ICG and NIR-accommodated devices have already entered the surgical theatre (Zehri et 
al., 2014; Schaafsma et al., 2011). We therefore evaluated LP-iDOPE as a new 
intra-operative nano-imaging agent. First, to estimate the in vivo biodistribution of 
LP-iDOPE in a brain tumor, we prepared 9L rat glioma cell implantation models. On 7 
days after implantation, we followed the brain tumor growth using 7T-MRI, and then 
injected LP-iDOPE intravenously through the rat tail vein. Next, we performed 
consecutive NIR fluorescence imaging 1 day and 7 days after injection with LP-iDOPE. 
As shown in Fig. 3, we observed specific accumulation of LP-iDOPE in the brain tumor, 
by comparing the tumor position in the MRI (pre-operation) with that in the NIR 
(intra-operation). We speculate that breakdown of the blood-brain barrier (BBB) in the 
brain tumor and the EPR effect allows LP-iDOPE to concentrate in the tumor region 1 
day after injection with LP-iDOPE (Bhaskar et al., 2010). In contrast, the fluorescence 
intensity of LP-iDOPE completely disappeared from the tumor region 7 days after 
injection with LP-iDOPE (Jain and Stylianopoulos, 2010). Additionally, to confirm the 
accumulation of LP-iDOPE into the reticuloendothelial system, we performed the ex 
vivo NIR fluorescence imaging for the lung, liver, spleen, and kidneys (Fig. S3 in 
Supporting information). It is evident that LP- iDOPE accumulates specifically into the 
brain tumor at 1 day after injection. After 7 days, the accumulation of NIR in all tissues 
and in the tumor decreased. The key in tumor imaging is to improve the specificity and 
to distinguish tumors from normal tissues. Fig. 4 shows tumor-specific localization of 
LP-iDOPE and creates a “white stars in a black sky” _effect (Vahrmeijer et al., 2013). 
We were therefore able to identify the structures that need to be resected in brain tumor 
surgery. In addition, to assess the use of LP-iDOPE in intra-operative surgical resection, 
we determined the tumor to normal (T/N) ratio. To take examples discussed in the T/N 
ratio in brain tumors, those of 5-ALA and IRDye 800CW-conjugated RGD peptide 
which integrin b3 recognizes was 5 hold and 16–80 hold (reflecting the different 
expression levels of integrin b3 in brain tumors), respectively (Swanson et al., 2015; 
Huang et al., 2012). Therefore, as shown in Fig. 5, the signal intensity and the T/N ratio 
of LP-iDOPE (16.3 hold, n = 2) is sufficient for in vivo brain tumor imaging and for 
assisting neurosurgeons with accurate resection of brain tumors. The accumulation of 
LP-iDOPE on the brain tumor region was high compared with other organs, such as 
liver, spleen, and kidneys due to the breakdown of BBB (Fig. 5). On the other hand, the 
accumulation of LP-iDOPE on the brain normal region was extremely low due to the 
normal BBB at that region (Fig. 5). Finally, based on a combination of our results and 
those of previous clinical trials on ICG fluorescence-guided tumor surgery, we propose 
a protocol using LP-iDOPE: (i) injection of LP-iDOPE 1 day before the operation; (ii) 
resection of the brain tumor region, with a few margins, under irradiation at the 
excitation value of LP-iDOPE (around 780 nm) using a light-emitting diode (LED) 
device; (iii) irradiation at the absorption value of LP-iDOPE (around 810 nm) on a few 
remaining tumor margins using a LED device to induce cancer cell death with 
photodynamic therapy (PDT) (Onoyama et al., 2014; Yi et al., 2014), and (iv) 
noninvasive irradiation from the skull at the absorption value of LP-iDOPE (around 810 
nm) using a LED device to delay or reduce the risk of cancer recurrence (Fig. S4 in 
Supporting information). We suggest that this protocol permits the intra-operative 
image-guided brain tumor surgery (Fig. 6a) and the PDT-guided tumor cell death in 
brain tumor marginal regions remaining after surgery (Fig. 6b). Furthermore, the 
post-operative PDT treatment in terms of noninvasion may be 
useful for post-operative aftercare (Fig. S4 in Supporting informa-tion). This 
combination of LP-iDOPE with NIR fluorescence (detection and resection) and a beam 
(PDT) system enables maximum safety in removal of the brain tumor.  
 
4. Conclusions 
 In this study, we evaluated the use of liposomally formulated phospholipid-conjugated 
ICG, denoted by LP-iDOPE, as clinically translatable fluorescent nanoparticles for 
brain tumor surgery. We examined the characteristics of LP-iDOPE relevant to its use as 
a NIR fluorescence imaging dye, such as its optical properties, particle size, and 
tumor-specific localization. LP-iDOPE imaging with MRI and a NIR fluorescence 
imager, with LP-iDOPE injection 1day before surgery, effectively fills the gap between 
pre-operative imaging and intra-operative reality in detecting tumor and normal brain 
tissues. Therefore, the use of LP-iDOPE for brain tumor surgery may have the potential 
to overcome the limitations of traditional intra-operative brain tumor surgery, by 
highlighting tumor borders in real time and enabling treatment of surgically remaining 
cancer cells with PDT. In addition, the combination of LP-iDOPE with a LED device in 
terms of noninvasive treatment may useful for post-operative aftercare of brain tumor 
surgery (Fig. S4 in Supporting information). Finally, NIR fluorescence image-guidance 
of brain tumor surgery with LP-iDOPE will improve patient management by 
demarcating tumor borders clearly in real time, in terms of the efficiency of brain tumor 
resections, improvement of QOL, and elongation of survival times (Butte et al., 2014; 
Barone et al., 2014).  
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Fig. 1. (a) Schematic and 
partial membrane structure of 
LP-iDOPE. Partial membrane 
structure of LP-iDOPE without 
cholesterol and PEG: gray, 
DOPC; green, ICG 
fluorophore of iDOPE; and 
orange, DOPE region of 
iDOPE. (b) Averaged volume 
of LP-iDOPE. Diameter 
distribution of LP-iDOPE. 
iDOPE/DOPC molar ratio was 
0.1 (10 mol% iDOPE). Gray 
bars are differential frequency 
and red line is cumulative 
frequency. 
 Fig. 2. Optical excitation (dashed line) and emission (full line) of the ICG fluorophore. 
Normalized vis-NIR absorption spectra of LP-iDOPE (black) and ICG (red) in PBS. 
Concentrations of the ICG fluorophore of LP-iDOPE and ICG were 1 mM. 
  
Fig. 3. (a) in vivo MRI and (b) ex vivo NIR fluorescence imaging. Longitudinal 
observation MRI and NIR fluorescence images of rat bearing 9L tumors: day 1 and day 
7 after intravenous injection with LP-iDOPE. 
  
Fig. 4. Ex vivo NIR fluorescence imaging of brain surface. Longitudinal observation 
NIR fluorescence images of rat bearing 9L tumors: day 1 and day 7 after intravenous 
injections with LP-iDOPE. 
  
 
Fig. 5. Longitudinal observation NIR fluorescence intensity of LP-iDOPE in brain, liver, 
spleen, and kidney of rat bearing 9L tumors: day 1 (black) and day 7 (gray) after 
intravenous injection with LP-iDOPE (n = 2). Brain_T: tumor region of brain, Brain_N: 
normal region of brain. 
  
Fig. 6. ICG fluorescence guided tumor surgery. (a) Intra-operative irradiation at 
excitation value of LP-iDOPE (around 780 nm) to detect brain tumor using LED device 
and (b) post-resection irradiation at absorption value of LP-iDOPE (around 810 nm) 
emitted from a LED device to induce cancer cell death by PDT on brain tumor marginal 
region remaining after surgery. 
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III. In vivo evaluation of photodynamic therapy using LP-iDOPE  
 
1. Goal 
 In the previous chapter, we designed and developed LP-iDOPE which is a liposomally 
formulated phospholipid-conjugated ICG, and confirmed with fluorescence imaging 
that LP-iDOPE accumulated in tumor tissue for a rat glioma model. We are interested in 
producing ICG derivatives with phospholipid moiety resulted in new linkers for 
anchoring ICG fluorophore to the liposome. 
In this chapter, we evaluate the efficacy of photodynamic therapy (PDT) when using 
LP-iDOPE in vivo. We carried out LP-iDOPE administration and NIR irradiation for rat 
glioma models and observed the longitudinal tumor growth using MRI.  
 
2. MATERIALS & METHODS 
2.1. Liposome 
 LP-iDOPE was prepared as previously reported (A. Suganami et al., 2015 Dec 30). 
Cholesterol (1.0 mM, Nippon Fine Chemical Co., Ltd., Tokyo, Japan), 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC, 9.1 mM, NOF Corporation, Tokyo, 
Japan), N-(carbonyl- methoxypolyethyleneglycol 5000)-1,2-distearoly-sn-glycero-3- 
phosphoethanolamine sodium salt (DSPE-PEG, 0.5 mM, NOF Corporation), and 
iDOPE (0.9 mM, iDOPE/DOPC molar ratio of 1/10) were dissolved in a mixed organic 
solvent consisting of CH3OH/CHCl3 (volume ratio: 1/9).  
 
2.2. Cells 
 9L gliosarcoma cell lines originating in rat were cultured in DMEM (D5796, 
Sigma-Aldrich Japan, Japan) supplemented with 10% FCS and 1% Penicillin and 
streptomycin in a humidified atmosphere of 5% CO2 at 37˚C. 
 
2.3. Animal models 
 Male Fisher 344 rats (150-200 g, 8-9 weeks old, n = 23, CLEA Japan, inc., Tokyo, 
Japan) were used. The animals were anesthetized with 2.0% isoflurane and placed in a 
stereotaxic apparatus (SR-5R, SM-15R, Narishige group, Japan). A burr hole in the 
skull was made at 1 mm anterior to bregma and 3.5 mm right of the midline. A 
30-gauge needle was inserted to a depth of 3.0 mm ventral from the dura. The 9L tumor 
cells (1 × 105 in 2µL medium) were slowly injected into the brain (Iwadate et al., 2005). 
This animal experiment was performed in accordance with the guideline for the proper 
care and use of laboratory animals, and law No. 105 and notification No. 6 of the 
Japanese Government. 
 
2.4. NIR irradiation device 
 The NIR irradiation device (DVL-20, Asuka medical INC, Japan) was connected to a 
probe (E400S-PL, Fuji SLI, Japan) via an optical fiber. The tip of the irradiation probe 
was cone-shaped to scatter NIR light. A single wavelength of 808 nm was used (Fig. 1). 
 
2.5. Optimization of NIR irradiation power 
 To optimize the NIR irradiation condition for rats, ten days after the implantation of 9L 
cells, rats were randomly divided into 4 groups to receive different levels of irradiation 
strength: 1.0 Watt (W), 1.5 W, 2.0 W and a non-irradiation group as a control. 
LP-iDOPE (14.0 mg/kg) was injected into a tail vein, and gadolinium-enhanced MRI 
was acquired 24 hours after the injection. A NIR irradiation probe was inserted into the 
brain of an animal firmily held in a stereotactic apparatus with MRI-guidance, and NIR 
irradiation was applied at the selected strength. The LP-iDOPE injection and NIR 
irradiation was repeated 2 weeks later, after which body weight and tumor volume were 
mesured.  
We used laser light of wavelength 808 nm, which is absorbed by LP-iDOPE. The total 
calorific output was 240 J for each application. The irradiation was repeated in a 500 
msec on 500 msec off pattern to avoid heat damage of the tissue. 
 
2.6. Treatment for glioma rats 
 Rats (n = 16) were divided into 4 different treatment strategies consisting of (1) 
LP-iDOPE + NIR (n = 5), (2) LP-iDOPE alone (n = 3), (3) NIR alone (n = 3), and (4) 
saline control (n = 5) groups. Two days after the 9L cell implantation, LP-iDOPE 
(14.0mg/kg, LP-iDOPE + NIR and LP-iDOPE groups) or saline (NIR and saline control 
groups) was administered to the rats through a tail vein (day 0). NIR light was only 
applied to the LP-iDOPE + NIR and NIR alone groups. Gadolinium-enhanced MRI was 
obtained to check localization and volume of the tumor in the brain before treatment 24 
hours after the LP-iDOPE or saline administration (Fig. 2). An NIR irradiation probe 
was inserted into the brain as described in Section 2.5. The tip of the probe was placed 
on the upper boundary of the tumor with guidance provided by MRI.  
 
2.7. MRI measurement 
 To evaluate the tumor volume longitudinally, MRI was measured for all animals every 
7 days (Fig. 3). Rats were anesthetized with 2% isoflurane (Pfizer japan inc., Japan) and 
injected with meglumine gadoterate (220~280mg/kg i.p., Gd-DOTA, Magnescope®, 
Guerbet Japan inc., Japan, 0.283 g/ml) to enhance the glioma. Images were acquired 
with a 7-T animal MRI system (Magnet: BioSpec 70/20 U SR, Bruker, Germany, 
Console: Bruker Biospin, Germany). Tumor volume was calculated from T1W images 
as the Gd-DOTA-enhanced area across all slices using image analysis software 
(Osirix®, Pixmeo, Switzerland).  
 
2.8. Immunohistology 
 After MRI acquisition, the rats were deeply anesthetized and perfused through the 
ascending aorta with 4% paraformaldehyde. After euthanization, the brains were 
carefully removed for pathological assessment. Frozen tissue sections of the brain 
specimens 10 µm thickness were prepared for anti-CD8 antibody and macrophage 
(RM-4) staining.  
3. RESULTS and DISCUSSION 
3.1. Optimization of NIR irradiation 
 LP-iDOPE was injected into the tumor bearing rats and they were NIR irradiated 24 
hours later and then again after 2 weeks. We measured the body weight and MRI 
longitudinally for each group: 1.0 W group (n = 2), 1.5 W group (n = 2), 2.0 W group (n 
= 2), and non-irradiation group (n = 1).  
 Figure 4 shows longitudinal body weight alteration. For the 2.0 W group, two rats (2/2) 
died during the second opplication of the NIR irradiation. The body weight showed a 
descending trend for the 1.0 W, 2.0 W and non-irradiation groups from approximately 3 
weeks after the implantation. On the other hand, body weight for the 1.5W group 
showed an graduall increase. Longitudinal MR images are presented in figure 5. A 
typical image for the 1.5W group at day 28 showed high contrast that is thought to be the 
necrotic region of the tumor. From these results, we decided to use an irradiation strength 
of 1.5 W with total heat energy of 240 J. The irradiation cycle was for 1 sec (exposure 
time: 300 msec, interval time :700 msec) and the irradiation was repeated 600 times. 
The total required time was 10 min.  
 
3.2. Longitudinal evaluation of tumor volume with MRI measurement 
 Tumor volume before irradiation (day 1) was 0.9 ± 0.29 mm3. The small tumor is a 
model for tumor that may remain but be invisible after the surgery. Figure 6 shows the 
longitudinal tumor progression for each group. At Day 29, tumor volume for the 
LP-iDOPE + NIR irradiation group was 299.0 ± 154.9 mm3 (n = 5), for the LP-iDOPE 
alone group was 337.1 ± 97.8 mm3 (n = 3), for the NIR irradiation group was 418.5 ± 
55.8 mm3 (n = 3), and for the saline control was 307.8 ± 125.0 mm3 (n = 5). The 
average tumor volume of the LP-iDOPE + NIR group was the smallest, however there 
was no significant difference with the other groups due to the large dispersion. Note that 
one animal in the LP-iDOPE + NIR group showed drastic therapeutic efficacy (Fig. 6, 
red dot). 
 
3.3. Immunohistology 
 In the RM-4 staining, the invasion of many macrophages was observed for the 
LP-iDOPE + NIR group, but not for the NIR irradiation or saline control group (Fig. 7). 
In the anti-CD8 staining, CD8+ T cells were observed not only for the LP-iDOPE + NIR 
group but also for the other groups. The results suggest that the combination of 
LP-iDOPE with NIR irradiation induced migration of macrophages. On the other hand, 
the migration of CD8 positive cells, which are killer T cells, was not affected by the 
treatment strategy. It is possible that the migrated macrophages induced for the 
LP-iDOPE + NIR group may activate the killer T cells and promote a tumor suppressive 
effect. 
 
4. Conclusion 
 We evaluated the therapeutic effect of PDT using LP-iDOPE for an in vivo rat glioma 
model. A NIR strength of 1.5W was found to be best for the PDT as the body weight 
was unaffected by irradiation. The average tumor volume for the LP-iDOPE + NIR 
group was smallest, but there was no significant difference between the other groups 
due to the large dispersion. For the LP-iDOPE + NIR irradiation group. Macrophages 
were observed, but not for the other groups. The LP-iDOPE + NIR group had a large 
dispersion in therapeutic effect, with one animal showing a drastic therapeutic efficacy. 
It is thought that further optimization of the irradiation parameters for our image-guided 
approach will improve the treatment effect. 
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Fig. 1. The NIR irradiation device (Left 
image: DVL-20, Asuka medical INC, 
Japan) was connected to a probe 
(E400S-PL, Fuji SLI, Japan) via an 
optical fiber. The tip of the irradiation 
probe was cone-shaped to scatter NIR 
light. The irradiating light had a single 
wavelength of 808 nm. 
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Fig. 2. Treatment: (a) 
Gadolinium-enhanced MRI was 
obtained to check the tumor 
localization and volume in the 
brain 24 hours after the LP-
iDOPE or saline administration. 
(b) An irradiation probe was 
inserted in to the brain guided 
by MR images. NIR irradiation 
condition: wavelength was 808 
nm, output was 1.5W, The 
irradiation cycle was for 1 sec 
(a 300 msec on 700 msec off) 
was repeated 600 times.
 
① Implantation of 9L cells
② LP-iDOPE i.v.
③ NIR irradiation
Fig. 3. Time Course of Treatment. Day 0: Two days after the 9L cell implantation, LP-
iDOPE (14.0mg/kg) or saline was administered to the rats through a tail vein. Day 1 : 
NIR irradiation. Day 1 to 29 : To evaluate the tumor volume longitudinally, magnetic 
resonance imaging (MRI) was measured for all animals every 7 days.
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Fig. 4. Longitudinal body weight alteration. Both rats from the 2.0W group died 
during the the second application of the NIR irradiation. The body weight showed a 
descending trend for the 1.0 W, 2.0 W and non-irradiation groups, from approximately 
3 weeks after the implantation.
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Fig. 5. Longitudinal MR images for each group; (a) 1.0 W group, (b) 1.5 W group, (c) 
2.0 W group, and (d) non-irradiation group.
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Fig. 6. Longitudinal tumor progression for each group. No significant difference 
occurred between the groups due to the large dispersion. Note that one animal in the 
LP-iDOPE + NIR group showed drastic therapeutic efficacy (red dot).
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Fig. 7. Results of immunostaining i.e.  (a) Macrophage (RM-4) . Diaminobenzidine (DAB) 
stains macrophages brown.
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Fig. 7. (b) CD8+ T-cells were stained brown by Diaminobenzidine (DAB).
 
IV. Conclusion 
 
 To realize our proposed theranostics concept, we first evaluated the use of liposomally 
formulated phospholipid-conjugated ICG, denoted by LP-iDOPE, as clinically 
translatable fluorescent nanoparticles for brain tumor surgery. We tested the 
characteristics of LP-iDOPE relevant to its use as a NIR fluorescence imaging dye, such 
as its optical properties, particle size, and tumor-specific accumulation. LP-iDOPE 
imaging with MRI and a NIR fluorescence imager, with a LP-iDOPE injection 1 day 
before surgery, effectively fills the gap between pre-operative imaging and 
intra-operative reality in detecting tumor and normal brain tissues.  
 
 Second, we evaluated the therapeutic effect of the PDT using LP-iDOPE in vivo. We 
administered LP-iDOPE and evaluated the compared NIR irradiation effect for rat 
glioma models. We found that a NIR intensity of 1.5W was best for the PDT. Tumor 
volume of the LP-iDOPE with NIR irradiation group was the smallest on average and 
many macrophages were observed. Although the LP-iDOPE with NIR irradiation group 
had large dispersion of the therapeutic effect, one animal showed drastic therapeutic 
efficacy. Further optimization of the image-guided approach will improve the PDT effect 
for LP-iDOPE strategies. 
 
 
 
 In addition to the LP-iDOPE with NIR irradiation strategy, we tried to develop two 
MRI sensor contrast agents for theranostic applications. First, we reported a 
methodology that enables the preparation of dendrimeric contrast agents sensitive to Ca2+ 
when starting from the monomeric analogue (Chem Commun (Camb). 2015 Feb 
18;51(14):2782-5). The Ca-triggered longitudinal relaxivity response of these agents is 
maintained even with structural changes due to synthetic transformation. The in vivo 
MRI studies in the rat cerebral cortex indicate that the diffusion properties of dendrimeric 
contrast agents have great advantages in comparison to the monomeric equivalents. 
 
 Second, using carbamoyl-PROXYL (CMP) as an MRI contrast probe we developed a 
novel approach for detecting minute disruptions in BBB induced by dietary cholesterol 
(Biochim Biophys Acta. 2011 Dec; 1810(12): 1309-16). 
 Gd-DTPA-enhanced magnetic resonance imaging (MRI) is a conventional method for 
blood-brain-barrier (BBB) permeability in vivo. It can visualize serious injuries of the 
BBB. MRI-signal dynamics, plasma cholesterol, matrix metalloproteinase (MMP-9, 
MMP-2), and the white blood cell profile were analyzed. For the MRI analysis, we 
compared brain region with surrounding area in each group. 
 In the surrounding area of normal diet (ND) -mice, CMP- or Gd-enhanced MRI-signal 
followed typical kinetics with a half-life of signal decay (τ(1/2)) approximately 8 or 
approximately 15 min, respectively. In cholesterol diet (CD)-mice, the MRI-signal 
increased continuously without decay. In the brain region of ND- and CD-mice, 
MRI-signal enhancement was not detected with Gd-DTPA. In the brain region of 
ND-mice, CMP-induced MRI-signal enhancement was negligible, while in CD-mice, it 
was significant (τ(1/2)>15 min). Hypercholesterolemia increased the plasma levels of 
MMP-9 and neutrophils. 
 
 The importance of these technologies will increase to realize the precision medicine, 
which will allow improvement of the rate of complete recovery due to early diagnosis 
and treatment, improving quality of life by reducing side effects, and improved decision 
making for more accurate surgery planning. In the study, our motivation for the 
development of the technology was to improve the quality of brain surgery for tumor 
extraction. Glioma is one of the most difficult diseases. I hope that our effort will 
contribute to the development of more effective treatment methods and make incurable 
diseases curable in the future. 
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